Hi there,
Bausch Health is still dealing with the fallout as a poorly management company (Valeant). In fact the company has been trading sideways every since its stock price cratered approximately 4 years ago.
Although the company was on generating positive momentum pre-pandemic, it suffered yet another setback. In the last quarter, it reported a net loss of $152 million on COVID-19 impacts and further litigation costs. The company also guided downwards for the balance of 2020.
Looking further out - there is nothing to get too excited about. Pre-pandemic, the company had guided to flat growth through 2022 and is reliant on the "significant seven" products. Although it is trying to diversify away from these products, there is no clear path to growth in the short to mid term.
Bottom line, the company is still booking litigation charges and growth is minimal. Not exactly a winning combination. The hit to the company's reputation is taking years to repair, and although it is underpinned by the significant seven, it has been (and remains) a long-term turnaround story.
Mat